Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
Date:5/2/2013

JERSEY CITY, N.J., May 2, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report first quarter 2013 financial results after the NASDAQ Global Market closes on Thursday, May 9. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the first quarter and provide a corporate update.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. 

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society.  Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada.  Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.  The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey , VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark , Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
2. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
4. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
5. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
7. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
10. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):